IDO1 and pancreatic neoplasm: NLG919 inhibits the expression of IDO-1, which converts tryptophan (Trp) into kynurenine (Kyn), thus modulating the immunosuppressive TME in pancreatic cancer by increasing the proportion of DCs and T cells while reducing the proportion of regulatory T cells (Tregs) [43,48].